应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09939 开拓药业-B
休市中 04-26 16:08:20
0.960
+0.020
+2.13%
最高
1.040
最低
0.940
成交量
147.50万
今开
1.040
昨收
0.940
日振幅
10.64%
总市值
4.30亿
流通市值
4.30亿
总股本
4.47亿
成交额
142.87万
换手率
0.33%
流通股本
4.47亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
万春医药下跌4.41%,报2.17美元/股
金融界 · 03:22
万春医药下跌4.41%,报2.17美元/股
4月26日艾力斯涨停分析:创新药,医药概念热股
证券之星 · 04-26 15:34
4月26日艾力斯涨停分析:创新药,医药概念热股
4月26日圣达生物涨停分析:合成生物,医药,化学原料药概念热股
证券之星 · 04-26 15:33
4月26日圣达生物涨停分析:合成生物,医药,化学原料药概念热股
开拓药业-B(09939):退回位于中国浙江省平湖市的土地使用权
智通财经 · 04-26 12:20
开拓药业-B(09939):退回位于中国浙江省平湖市的土地使用权
开拓药业-B(09939.HK)退回浙江土地使用权 料增全年利润243万人币
阿斯达克财经 · 04-26 12:18
开拓药业-B(09939.HK)退回浙江土地使用权 料增全年利润243万人币
国君晨报0426|医药、汽车、特斯拉
国泰君安证券研究 · 04-26 07:00
国君晨报0426|医药、汽车、特斯拉
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
证券之星 · 04-25 19:02
拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域
万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同
证券之星 · 04-25 18:02
万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同
4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股
证券之星 · 04-25 15:28
4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股
港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)
智通财经 · 04-25 13:46
港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)
【兴证医药】2024ASCO会议国产创新药品种梳理
兴证医药健康 · 04-25 11:46
【兴证医药】2024ASCO会议国产创新药品种梳理
国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速
智通财经 · 04-25 11:22
国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速
亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进
智通财经 · 04-25 10:47
亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进
A股开盘速递 | 医药板块反弹 业绩超预期股大涨
智通财经网 · 04-25 09:48
A股开盘速递 | 医药板块反弹 业绩超预期股大涨
【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告
金吾财讯 · 04-25 09:03
【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告
亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会
阿斯达克财经 · 04-25 08:12
亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会
华泰 | 医药:胰岛素续约降幅温和,国产替代加速
华泰睿思 · 04-25 07:41
华泰 | 医药:胰岛素续约降幅温和,国产替代加速
亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告
智通财经 · 04-25 07:02
亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告
国君医药|胰岛素集采结果出炉,国产替代有望提速
国泰君安证券研究 · 04-25 07:00
国君医药|胰岛素集采结果出炉,国产替代有望提速
万春医药上涨3.96%,报2.38美元/股
金融界 · 04-24 22:00
万春医药上涨3.96%,报2.38美元/股
加载更多
公司概况
公司名称:
开拓药业-B
所属市场:
SEHK
上市日期:
--
主营业务:
开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。
发行价格:
--
{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":0.96,"timestamp":1714118900021,"preClose":0.94,"halted":0,"volume":1475000,"delay":0,"floatShares":447499600,"shares":447499600,"eps":-2.6624813,"marketStatus":"休市中","marketStatusCode":7,"change":0.02,"latestTime":"04-26 16:08:20","open":1.04,"high":1.04,"low":0.94,"amount":1428730,"amplitude":0.106383,"askPrice":0.97,"askSize":150000,"bidPrice":0.96,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-2.6624813568895744,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714354200000},"adr":0,"listingDate":1590076800000,"adjPreClose":0.94,"openAndCloseTimeList":[[1714095000000,1714104000000],[1714107600000,1714118400000]],"volumeRatio":0.2091154979714561,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2430738182","title":"万春医药下跌4.41%,报2.17美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430738182","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430738182?lang=zh_cn&edition=full","pubTime":"2024-04-27 03:22","pubTimestamp":1714159356,"startTime":"0","endTime":"0","summary":"4月27日,万春医药(BYSI)盘中下跌4.41%,截至03:22,报2.17美元/股,成交6.42万美元。财务数据显示,截至2023年06月30日,万春医药收入总额87.5万美元,同比增长29.44%;归母净利润-1272.0万美元,同比增长31.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/27032240443008.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430245907","title":"4月26日艾力斯涨停分析:创新药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430245907","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430245907?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:34","pubTimestamp":1714116863,"startTime":"0","endTime":"0","summary":"证券之星消息,艾力斯涨停收盘,收盘价56.69元。该股于10点3分涨停,11次打开涨停,截止收盘封单资金为4.57万元,占其流通市值0.0%。4月26日的资金流向数据方面,主力资金净流出2114.2万元,占总成交额2.35%,游资资金净流出1546.44万元,占总成交额1.72%,散户资金净流入3660.64万元,占总成交额4.07%。近5日资金流向一览见下表:该股为创新药,医药概念热股,当日创新药概念上涨1.21%,医药概念上涨0.92%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600029640.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430643245","title":"4月26日圣达生物涨停分析:合成生物,医药,化学原料药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430643245","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430643245?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:33","pubTimestamp":1714116802,"startTime":"0","endTime":"0","summary":"证券之星消息,圣达生物涨停收盘,收盘价10.91元。该股于14点21分涨停,2次打开涨停,截止收盘封单资金为74.3万元,占其流通市值0.04%。4月26日的资金流向数据方面,主力资金净流入1510.57万元,占总成交额15.96%,游资资金净流出786.37万元,占总成交额8.31%,散户资金净流出724.2万元,占总成交额7.65%。近5日资金流向一览见下表:该股为合成生物,医药,化学原料药概念热股,当日合成生物概念上涨2.07%,医药概念上涨0.92%,化学原料药概念上涨0.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600029571.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430218141","title":"开拓药业-B(09939):退回位于中国浙江省平湖市的土地使用权","url":"https://stock-news.laohu8.com/highlight/detail?id=2430218141","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430218141?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:20","pubTimestamp":1714105217,"startTime":"0","endTime":"0","summary":"智通财经APP讯,开拓药业-B 发布公告,于2024年4月25日,卖方开拓药业(浙江)有限公司与买方浙江独山港经济开发区管理委员会订立协议,依据协议,卖方同意退回,而买方同意回收,位于中国浙江省平湖市的土地使用权,代价约为人民币2607万元。该土地坐落于中国浙江省平湖市独山港经济开发区中山路南侧、汇港路西侧的若干土地的土地使用权,面积约4万平方米。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111297.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430321331","title":"开拓药业-B(09939.HK)退回浙江土地使用权 料增全年利润243万人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2430321331","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430321331?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:18","pubTimestamp":1714105080,"startTime":"0","endTime":"0","summary":"开拓药业-B(09939.HK) 公布,其间接全资附属开拓药业(浙江)在取得位于中国浙江省平湖市的土地使用权后,受限于疫情的全球大流行以及公司新药开发策略的调整等原因,未对该土地进行实际开发。考虑公司综合发展策略,向浙江独山港经济开发区管理委员会退回该土地使用权,预计为集团带来2024年度现金流入约2,607万元人民币(下同),增加集团全年利润约243万元。集团所得款项预计用于公司核心产品KX826及GT20029的研发及商业化,并可补充一般营运资金。(jl/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220721143637635_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220721143637635_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345381/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430029497","title":"国君晨报0426|医药、汽车、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2430029497","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2430029497?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:00","pubTimestamp":1714086000,"startTime":"0","endTime":"0","summary":"4月特斯拉全球再次降价,支撑特斯拉短期销量修复,特斯拉产业链全面受益。事件简述:特斯拉发布2024年一季度财报,1Q24实现总收入213亿美元,同减9%,汽车收入174亿美元,同减13%。特斯拉1Q24交付38.7万辆汽车,同比下滑8.5%,环比下滑20.2%。此外,特斯拉2026年向普通用户交付电动半挂式卡车Semi。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650479400&idx=1&sn=fe2893c37bd1986e8e908d5573fd57bb&chksm=89868f09222bc394eac8ff55dc8e23808d37a29a46883c83246064680f4cbcaa4a32378ba74f&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430140653","title":"拓新药业:公司专注于核苷(核苷酸)类医药中间体及原料药,主要涵盖抗病毒、抗肿瘤和神经系统用药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2430140653","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430140653?lang=zh_cn&edition=full","pubTime":"2024-04-25 19:02","pubTimestamp":1714042932,"startTime":"0","endTime":"0","summary":"拓新药业董秘:公司研发成果请您关注公司披露的公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500039625.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430725974","title":"万润股份:公司生命科学与医药产品销售种类较多,不同产品售价不同,各报告期订单结构也存在不同","url":"https://stock-news.laohu8.com/highlight/detail?id=2430725974","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430725974?lang=zh_cn&edition=full","pubTime":"2024-04-25 18:02","pubTimestamp":1714039351,"startTime":"0","endTime":"0","summary":"公司一向依法合规经营,公司的财务报表和财务报告严格按照《企业会计准则》规定编制,能够公允的反映公司的财务状况、经营成果和现金流量。谢谢万润股份董秘:您好,公司根据实际经营情况进行存货管理,公司2024年一季度末存货较2023年末的存货减少,后续存货情况请见公司的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500038742.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430421337","title":"4月25日常山药业涨停分析:化学原料药,创新药,医药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430421337","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430421337?lang=zh_cn&edition=full","pubTime":"2024-04-25 15:28","pubTimestamp":1714030125,"startTime":"0","endTime":"0","summary":"证券之星消息,常山药业涨停收盘,收盘价11.77元。该股于9点31分涨停,未打开涨停,截止收盘封单资金为1.57亿元,占其流通市值1.45%。4月25日的资金流向数据方面,主力资金净流入2.19亿元,占总成交额41.29%,游资资金净流出1.31亿元,占总成交额24.68%,散户资金净流出8800.39万元,占总成交额16.61%。近5日资金流向一览见下表:该股为化学原料药,创新药,医药概念热股,当日化学原料药概念上涨2.05%,创新药概念上涨1.85%,医药概念上涨1.42%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500026171.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430440384","title":"港股概念追踪 |2024年医药流通企业并购整合趋势有望进一步加速 龙头国企受关注(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430440384","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430440384?lang=zh_cn&edition=full","pubTime":"2024-04-25 13:46","pubTimestamp":1714024003,"startTime":"0","endTime":"0","summary":"据新京报,近日,北京市卫健委、市中医药管理局联合发布《北京市“优质服务基层行”活动和社区医院建设三年行动方案》,加强北京市基层医疗卫生机构服务能力建设。到2025年,实现人财物乡村一体化管理的村卫生室比例力争达到60%以上。值得注意的是,新一轮国企改革亦强调医药健康领域的专业化整合,医药流通行业国资密集,叠加政策驱动下,在2024年这一时间点,国内医药流通企业并购整合趋势有望进一步加速,龙头集中度或将进一步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109584.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430441921","title":"【兴证医药】2024ASCO会议国产创新药品种梳理","url":"https://stock-news.laohu8.com/highlight/detail?id=2430441921","media":"兴证医药健康","top":-1,"share":"https://www.laohu8.com/m/news/2430441921?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:46","pubTimestamp":1714016760,"startTime":"0","endTime":"0","summary":"在任何情况下,作者及作者所在团队、兴业证券股份有限公司不对任何人因使用本平台中的任何内容所引致的任何损失负任何责任。本平台旨在沟通研究信息,交流研究经验,不是兴业证券股份有限公司研究报告的发布平台,所发布观点不代表兴业证券股份有限公司观点。任何完整的研究观点应以兴业证券股份有限公司正式发布的报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4NjAxNzEzNw==&mid=2650184762&idx=1&sn=f89f30ba7455571df18cb4e5bc143a30&chksm=86fc0db66d00eb1ce1d29c08a3f933d69da5e42befc0ac5e4517882a7f812187cb34ce92a31b&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430445133","title":"国投证券:行业国资密集 24年医药流通企业并购整合趋势有望进一步加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430445133","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430445133?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:22","pubTimestamp":1714015370,"startTime":"0","endTime":"0","summary":"值得注意的是,新一轮国企改革亦强调医药健康领域的专业化整合,医药流通行业国资密集,叠加政策驱动下,在2024年这一时间点,国内医药流通企业并购整合趋势有望进一步加速,龙头集中度或将进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109557.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430445348","title":"亚盛医药-B(06855.HK):四项研究入选ASCO年会,耐立克?治疗SDH缺陷型GIST 最新进","url":"https://stock-news.laohu8.com/highlight/detail?id=2430445348","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430445348?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:47","pubTimestamp":1714013242,"startTime":"0","endTime":"0","summary":"亚盛医药-B (06855.HK)发布公告,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中一项获口头报告。这三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克?)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ ROS1三联抑制剂APG-2449。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511303287ad5026&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042511303287ad5026&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430946412","title":"A股开盘速递 | 医药板块反弹 业绩超预期股大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2430946412","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430946412?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:48","pubTimestamp":1714009737,"startTime":"0","endTime":"0","summary":"4月25日,A股早盘震荡走弱,盘面上,医药股集体反弹,减肥药板块领涨。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240425/20240425095203_63903.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240425/20240425095203_63903.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109508.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430419821","title":"【港股通】亚盛医药-B(06855)四项临床研究入选ASCO年会 耐立克®获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2430419821","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2430419821?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:03","pubTimestamp":1714006995,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)宣布,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中耐立克®获口头报告。这三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克®)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ROS1三联抑制剂APG-2449。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210510/ZGJjYTkxOGYyMGNlOTUwNjQ0NzUyMDkw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935736","is_publish_highlight":false,"gpt_icon":0},{"id":"2430415439","title":"亚盛医药-B(06855.HK)四项临床研究入选美国临床肿瘤学会年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2430415439","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430415439?lang=zh_cn&edition=full","pubTime":"2024-04-25 08:12","pubTimestamp":1714003920,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK) 公布,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会(ASCO)年会,其中一项获口头报告。该三个重点品种分别为中国首个且唯一获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(HQP1351;商品名:耐立克)、Bcl-2选择性抑制剂APG-2575、和FAK/ALK/ROS1三联抑制剂APG-2449。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-24 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201214152342289_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201214152342289_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344840/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430141984","title":"华泰 | 医药:胰岛素续约降幅温和,国产替代加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430141984","media":"华泰睿思","top":-1,"share":"https://www.laohu8.com/m/news/2430141984?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:41","pubTimestamp":1714002060,"startTime":"0","endTime":"0","summary":"核心观点价:价格策略分化,整体保留合理利润空间本次胰岛素集采价格整体降幅约3.8%,其中二代平均降幅约2.4%,三代平均降幅约5.2%。量:格局变化不大,龙头国产替代加速本次集采共报量2.4亿支,且A类中标厂商较多,集采前后整体格局变化不大,但国产厂家份额有所提升,龙头国产替代加速进行,国产小厂家份额变化不大,进口份额下降。如因侵权行为给华泰证券造成任何直接或间接的损失,华泰证券保留追究一切法律责任的权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649760402&idx=3&sn=146cc6034103993a7d8ef51cf9400d60&chksm=89c7be69534dc170d43e4afc515ea21f2b96741a5bd501b68c45300e1c47d9bb555b6921f7f8&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2430908364","title":"亚盛医药-B(06855):四项研究入选ASCO年会,耐立克®治疗SDH缺陷型GIST 最新进展获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2430908364","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430908364?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:02","pubTimestamp":1713999730,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚盛医药-B 发布公告,公司三个重点品种的四项临床研究入选2024年美国临床肿瘤学会年会,其中一项获口头报告。一年一度的ASCO年会是全球肿瘤领域最重要、最权威的学术交流盛会,将展示当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术。本届ASCO年会将于2024年5月31日2024年至6月4日在美国伊利诺伊州芝加哥 McCormick会议中心以线上线下结合的形式举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109452.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430416650","title":"国君医药|胰岛素集采结果出炉,国产替代有望提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2430416650","media":"国泰君安证券研究","top":-1,"share":"https://www.laohu8.com/m/news/2430416650?lang=zh_cn&edition=full","pubTime":"2024-04-25 07:00","pubTimestamp":1713999600,"startTime":"0","endTime":"0","summary":"事件:2024年4月23日,国家组织药品联合采购办公室发布公告,公示胰岛素专项接续采购拟中选结果。本批集采预计于5月开始在全国落地实施,与上一轮胰岛素集采平稳有序衔接。与之同时,国产胰岛素报价积极,甘李药业4款产品中选A类、通化东宝6款产品中选A类、联邦制药6款产品中选A类,预计国产胰岛素将迎来进口替代的持续提速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650479374&idx=4&sn=a4ac1d9e8dfaa23c733b0c7de07ecb2c&chksm=89c459b821527cda39f36ca761d6e1b57cbd839aff97146c853a0c88365fe80dafd9d5ee4638&scene=0#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2429514634","title":"万春医药上涨3.96%,报2.38美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429514634","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429514634?lang=zh_cn&edition=full","pubTime":"2024-04-24 22:00","pubTimestamp":1713967233,"startTime":"0","endTime":"0","summary":"4月24日,万春医药(BYSI)盘中上涨3.96%,截至22:00,报2.38美元/股,成交5995.0美元。财务数据显示,截至2023年06月30日,万春医药收入总额87.5万美元,同比增长29.44%;归母净利润-1272.0万美元,同比增长31.2%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/24220040393487.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.0805},{"period":"1month","weight":0.119},{"period":"3month","weight":-0.254},{"period":"6month","weight":-0.6569},{"period":"1year","weight":-0.83},{"period":"ytd","weight":-0.4233}],"compareEarnings":[{"period":"1week","weight":0.088},{"period":"1month","weight":0.0768},{"period":"3month","weight":0.1065},{"period":"6month","weight":0.0145},{"period":"1year","weight":-0.1103},{"period":"ytd","weight":0.0354}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家临床阶段新药开发商,专注于研究癌症药物及其他雄激素受体(AR)相关疾病药物。该公司的主要在研药物是普克鲁胺。该药物正在中国进行转移性去势抵抗性前列腺癌(mCRPC)的III期临床试验。该公司处于临床阶段在研药物还包括一种II期小分子在研药物Pyrilutamide、一种II期单克隆抗体在研药物ALK-1、一种I期mTOR抑制剂Detorsertib、以及一种hedgehog信号转导途径抑制剂GT1708F。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.058646},{"month":2,"riseRate":0.75,"avgChangeRate":0.213088},{"month":3,"riseRate":0.25,"avgChangeRate":0.062774},{"month":4,"riseRate":0.75,"avgChangeRate":0.55435},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.091618},{"month":6,"riseRate":0.25,"avgChangeRate":-0.077338},{"month":7,"riseRate":0.75,"avgChangeRate":0.030119},{"month":8,"riseRate":0.25,"avgChangeRate":-0.047081},{"month":9,"riseRate":0,"avgChangeRate":-0.284122},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084422},{"month":11,"riseRate":0.75,"avgChangeRate":0.089012},{"month":12,"riseRate":0.25,"avgChangeRate":-0.241375}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}